[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2016019505A1 - Use of eubacterium in the prevention and treatment for colorectal cancer related diseases - Google Patents

Use of eubacterium in the prevention and treatment for colorectal cancer related diseases Download PDF

Info

Publication number
WO2016019505A1
WO2016019505A1 PCT/CN2014/083688 CN2014083688W WO2016019505A1 WO 2016019505 A1 WO2016019505 A1 WO 2016019505A1 CN 2014083688 W CN2014083688 W CN 2014083688W WO 2016019505 A1 WO2016019505 A1 WO 2016019505A1
Authority
WO
WIPO (PCT)
Prior art keywords
eubacterium
eubacterium eligens
eligens
staff
atcc
Prior art date
Application number
PCT/CN2014/083688
Other languages
French (fr)
Inventor
Qiang FENG
Dongya ZHANG
Chuan Liu
Liang Xiao
Longqing TANG
Jun Wang
Original Assignee
Bgi Shenzhen Co., Limited
Bgi Shenzhen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bgi Shenzhen Co., Limited, Bgi Shenzhen filed Critical Bgi Shenzhen Co., Limited
Priority to CN201480080819.1A priority Critical patent/CN106573044B/en
Priority to PCT/CN2014/083688 priority patent/WO2016019505A1/en
Publication of WO2016019505A1 publication Critical patent/WO2016019505A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales

Definitions

  • the invention relates to microbiology, specifically, this invention relates to Eubacterium bacterial strains in the treatment and prevention of colorectal cancer-related diseases in the application, and also involves the composition comprising Eubacterium bacteria and its application.
  • CRC Colorectal cancer
  • IBD inflammatory bowel disease
  • CRC colorectal cancer
  • ulcerative colitis ulcerative colitis
  • the human gut microflora which contains about 100 trillion microbial organisms, plays a critical role in maintaining host health, both in the gastrointestinal tract and systemically through the absorption of metabolites (e. g. vitamins and short chain fatty acids) (Moore WE, Holdeman LV (1974) Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 27: 961-979, incorporated herein by reference) .
  • metabolites e. g. vitamins and short chain fatty acids
  • Embodiments of the present disclosure seek to solve at least one of the problems existing in the prior art to at least some extent.
  • the present invention is based on the following findings by the inventors:
  • gut microbiota has become a major research area in human disease, including colorectal cancer (CRC) , one of the commonest causes of death among all types of cancers.
  • CRC colorectal cancer
  • MWAS Metagenome-Wide Association Study
  • the inventors identified 2 probiotic bacteria.
  • the inventors validated the probiotic bacteria in animal experiment related to colitis and CRC respectively. Results from the animal experiment demonstrated the ability of Eubacterium ventriosum and Eubacterium eligens to prevent and treat both colitis and colorectal cancer effectively.
  • Fig. 1 shows distribution of P-value association statistics of all microbial genes in this study.
  • the association analysis of CRC p-value distribution identified a disproportionate over-representation of strongly associated markers at lower P-values, with the majority of genes following the expected P-value distribution under the null hypothesis. This suggests that the significant markers likely represent true rather than spurious associations.
  • Fig. 2 Protective effects of intragastric administration of Eubacterium ventriosum ATCC 27560, Eubacterium ventriosum L2-12, Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020, Eubacterium eligens TSDC10.2-1.1 respectively on DSS-induced colitis in C57Bl/6J considering (A) weight loss, (B) disease activity index and (C) Colon length. Data are represented as mean ⁇ standard error. Different asterisks (*) indicate significant differences (*P ⁇ 0.05, **P ⁇ 0.01, ***p ⁇ 0.001) .
  • FIG. 3 Quantification using ELISA of (A) TNF- ⁇ and (B) IL-10 in colons obtained at day 15 after induction of colitis. Data are represented as mean ⁇ standard error. Different asterisks (*) indicate significant differences (*P ⁇ 0.05, **P ⁇ 0.01, ***p ⁇ 0.001)
  • Fig. 4 Effect of Eubacterium ventriosum ATCC 27560, Eubacterium ventriosum L2-12, Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020, Eubacterium eligens TSDC10.2-1.1 respectively treatment on (A) _Disease activity indices and (B) colon histopathology. Different asterisks (*) indicate significant differences (*P ⁇ 0.05, **P ⁇ 0.01, ***p ⁇ 0.001)
  • Fig. 5 Eubacterium ventriosum ATCC 27560, Eubacterium ventriosum L2-12, Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020, Eubacterium eligens TSDC10.2-1.1 respectively modulate colonic gene expression in BABL/C mice (relatived with ⁇ -actin) . Data are represented as meant ⁇ standard error. Different asterisks (*) indicate significant differences (*P ⁇ 0.05, **P ⁇ 0.01, ***p ⁇ 0.001) .
  • the present application provides Eubacterium eligens or Eubacterium ventriosum for use in the prevention or treatment of colitis and/or colorectal cancer.
  • the present application provides use of Eubacterium eligens or Eubacterium ventriosum for manufacture of a medicament for prevention or treatment of colitis and/or colorectal cancer.
  • the present application provides a method for the prevention or treatment of colitis and/or colorectal cancer comprising administering an effective amount of Eubacterium eligens or Eubacterium ventriosum to a patient in need thereof.
  • the present application provides a kit comprising Eubacterium eligens or Eubacterium ventriosum and instructions for its use as a medicament.
  • the present application further provides a pharmaceutical composition comprising Eubacterium eligens or Eubacterium ventriosum and a pharmaceutically acceptable vehicle.
  • the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC10.2-1.1.
  • the Eubacterium ventriosum is a strain selected from the group consisting of Eubacterium ventriosum ATCC27560, Eubacterium ventriosum L2-12, and Eubacterium ventriosum STAFF 1042.
  • the Eubacterium eligens or Eubacterium ventriosum is administered in the form of living Eubacterium eligens or Eubacterium ventriosum or metabolites thereof.
  • Example 1 Identifying probiotic bacteria from 128 Chinese individuals
  • BMI body mass index
  • eGFR epidermal growth factor receptor
  • DM diabetes mellitus type 2.
  • DNA library construction was performed following the manufacturer's instruction (IIlumina HiSeq 2000 platform).
  • the inventors used the same workflow as described previously to perform cluster generation, template hybridization, isothermal amplification, linearization, blocking and denaturation, and hybridization of the sequencing primers (Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012), incorporated herein by reference) .
  • the inventors constructed one paired-end (PE) library with insert size of 350bp for each sample, followed by a high-throughput sequencing to obtain around 30 million PE reads of length 2x100bp.
  • High quality reads were extracted by filtering low quality reads with ‘N’ base, adapter contamination and human DNA contamination from the raw data, and by trimming low quality terminal bases of reads at the same time. 751 million metagenomic reads (high quality reads) were generated (5.86 million reads per individual on average, Table 2) .
  • the inventors created a set of 2,110,489 (2.1M) genes that were present in at least 6 subjects, and generated 128 gene abundance profiles using these 2.1 million genes.
  • the inventors used the permutational multivariate analysis of variance (PERMANOVA) test to assess the effect of different characteristics, including age, BMI, eGFR, TCHO, LDL, HDL, TG, gender, DM, CRC status, smoking status and location, on gene profiles of 2.1M genes.
  • the inventors performed the analysis using the method implemented in package “vegan” in R, and the permuted p-value was obtained by 10,000 times permutations.
  • the inventors also corrected formultiple testing using “p. adjust” in R with Benjamini-Hochberg method to get the q-value for each gene.
  • BMI body mass index
  • DM diabetes mellitus type 2
  • HDL high density lipoprotein
  • TG triglyceride
  • eGFR epidermal growth factor receptor
  • TCHO total cholesterol
  • LDL low density lipoprotein
  • MWAS metagenome wide association study
  • a two-tailed Wilcoxon rank-sum test was used in the 2.1M (2,110,489) gene profiles.
  • the inventors got 140, 455 gene markers, _which were enriched in either case or control with P ⁇ 0.01 (Fig. 1) .
  • FDR false discovery rate
  • the inventors examined the taxonomic differences between control and CRC-associated microbiomes to identify microbial taxa contributing to the dysbiosis. For this, the inventors used taxonomic profiles derived from three different methods, as supporting evidence from multiple methods would strengthen an association. First, the inventors mapped metagenomic reads to 4650 microbial genomes in the IMG database (version 400) and estimated the abundance of microbial species included in that database (denoted IMG species) . Second, the inventors estimated the abundance of species-level molecular operational taxonomic units (mOTUs) using universal phylogenetic marker genes.
  • mOTUs species-level molecular operational taxonomic units
  • MLGs metagenomic linkage groups
  • the inventors For each IMG genome, using the NCBI taxonomy identifier provided by IMG, the inventors identified the corresponding NCBI taxonomic classification at species and genus levels using NCBI taxonomy dump files. The genomes without corresponding NCBI species names were left with its original IMG names, most of which were unclassified.
  • Clean reads (high quality reads in Example 1) were aligned to mOTU reference (total 79268 sequences) with default parameters (S. Sunagawa et al. , Metagenomic species profiling using universal phylogenetic marker genes. Nature methods 10, 1196 (Dec, 2013) , incorporated herein by reference) . 549 species level mOTUs were identified, including 307 annotated species and 242 mOTU linkage groups without representative genomes, which were putatively Firmicutes or Bacteroidetes.
  • the inventors constructed the colorectal cancer associated MLGs using the method described in the previous type 2 diabetes study as Qin et al. 2012, supra. All genes were aligned to the reference genomes of IMG database v400 to get genome level annotation. An MLG was assigned to a genome if > 50% constitutive genes were annotated to that genome, otherwise it was termed as unclassified. Total 87 MLGs with gene number over than 100 were selected as colorectal cancer associated MLGs. These MLGs were grouped based on the species annotation of these genomes to construct MLG species.
  • the inventors estimated the average abundance of the genes of the MLG species, after removing the 5% lowest and 5% highest abundant genes. Relative abundance of IMG species was estimated by summing the abundance of IMG genomes belonging to that species.
  • Parvimonas micra (q ⁇ 1.80x10 -5 )
  • Peptostreptococcus stomatis (q ⁇ 1.80x10 -5 )
  • Solobacterium moorei (q ⁇ 0.004331)
  • Fusobacterium nucleatum (q ⁇ 0.004565) were consistently enriched in CRC patient microbiomes across all three methods.
  • P. stomatis has been associated with oral cancer (S. Pushalkar et al. , Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC microbiology 12, 144 (2012) , incorporated herein by reference)
  • S. moorei has been associated with bacteremia (R. M.
  • micra is involved in the etiology of periodontis (B. H. Kremer et al. , Peptostreptococcus micros smooth and rough genotypes in periodontitis and gingivitis. Journal of periodontology 71, 209 (Feb, 2000) , incorporated herein by reference) , and it produces a wide range of proteolytic enzymes and uses peptones and amino acids as energy source (D. A. Murdoch, H. N. Shah, Reclassification of Peptostreptococcus magnus (Prevot 1933) Holdeman and Moore 1972 as Finegoldia magna comb. nov.
  • mice Ten to twelve weeks old C57BL/6J mice used for DSS-induced colitis study were prepared in SPF condition. After acclimatization, part of mice have ad libitum access to drinking water containing 3.5-5% DSS (dextran sodium sulfate) for five days for colitis induction.
  • DSS extran sodium sulfate
  • C57BL/6J mice were purchased from Laboratory Animal Center of Southern Medical University, China.
  • Eubacterium ventriosum ATCC 27560 and Eubacterium eligens ATCC 27750 were purchased from American Type Culture Collection (ATCC) .
  • Eubacterium ventriosum L2-12 Estelle Devillard, Freda M. McIntosh, Sylvia H. Duncan, and R. John Wallace (March 2007) . Metabolism of Linoleic Acid by Human Gut Bacteria: Different Routes for Biosynthesis of Conjugated Linoleic Acid. Journal of Bacteriology 189 (6) : 2566-2570.
  • mice were observed daily and recorded clinical measurements.
  • Body weights and the disease activity index (Table 6) (Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin , LS, et al. 2009 Distinct cytokine patterns identified from multiplexprofiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis; 15 (3) : 341-52. incorporated herein by reference. )
  • a composite score reflecting clinical signs of the disease i. e. perianal soiling, rectal bleeding and diarrhea
  • the colon was removed, dissected free of fat and mesentery, carefully opened, and cleaned with PBS (phosphate buffered saline) . Colon length was measured. Colonic damage and inflammation were assessed blindly according to the Wallace criteria. Colon was also collected into liquid nitrogen and stored at-80°C for ELISA (Enzyme Linked Immunosorbent Assay) examinations.
  • PBS phosphate buffered saline
  • the inventors explored the anti-inflammatory effects in vivo by testing the ability of E. eligens ATCC 27750, STAFF 1020, TSDC10.2-1.1 and E. ventriosum L2-12, STAFF 1042, ATCC 27560 respectively to recover acute colitis induced by DSS.
  • a severe acute inflammatory was observed in the colitis control group after DSS treated, and no significant protective effect was observed in mice receiving sterile culture medium.
  • daily intragastric administration of 6 living Eubacterium strains respectively all resulted in a marked attenuation of colitis with reduced weight loss (Table 7, Fig.
  • ATCC 27560 represents Eubacterium ventriosum ATCC 27560; L2-12 represents Eubacterium ventriosum L2-12, STAFF 1042 represents Eubacterium ventriosum STAFF 1042, ATCC 27750 represents Eubacterium eligens ATCC 27750, STAFF 1020 represents Eubacterium eligens STAFF 1020, TSDC10.2-1.1 represents Eubacterium eligens TSDC10.2-1.1.
  • TNF- ⁇ tumor necrosis factor alpha
  • IL-10 anti-inflammatory IL-10
  • mice were challenged with azoxymethane (AOM, 10 mg/kg) at the age of 10 weeks followed by a 2.0% dextran sodium sulfate (DSS) treatment in the drinking water for 7 days beginning on week 2, week 5 and week 8 to induce colitis-associated colorectal cancer (CRC) .
  • BABL/c mice were purchased from Laboratory Animal Center of Southern Medical University, China.
  • RNA isolation and real-time polymerase chain reaction of cytokines tTotal RNA from colon was isolated using the Qiagen RNA isolation kit (Qiagen) according to the manufacturer’s instructions, and then was used to generate the cDNA template using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and real-time RT-PCR was performed as previously described (Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroen-terology 127: 777-791, incorporated herein by reference) .
  • mRNA expression of CD36, and PPAR ⁇ peroxisome proliferator-activated receptor ⁇
  • mice challenged with azoxymethane and DSS were euthanized in the tumor-bearing phase of the disease.
  • Those mice treated with E. eligens ATCC 27750 or E. eligens STAFF 1020 or E. eligens TSDC10.2-1.1 or E. ventriosum L2-12 or E. ventriosum STAFF 1042 or E. ventriosum ATCC 27560 shoeed increased mRNA expression of CD36 and PPAR ⁇ in the colon compared with medium-treated control group (Fig. 5, Table 9) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The application of microorganisms, particular Eubacterium strains, in treatment and prevention of colorectal cancer-related diseases is disclosed. The composition comprising the Eubacterium strains is involved.

Description

USE OF EUBACTERIUM IN THE PREVENTION AND TREATMENT FOR COLORECTAL CANCER RELATED DISEASES
CROSS-REFERENCE TO RELATED APPLICATION
None
FIELD
The invention relates to microbiology, specifically, this invention relates to Eubacterium bacterial strains in the treatment and prevention of colorectal cancer-related diseases in the application, and also involves the composition comprising Eubacterium bacteria and its application.
BACKGROUND
Colorectal cancer (CRC) is the third most common form of cancer and the second leading cause of cancer-related death in the Western world (Schetter AJ, Harris CRC (2011) Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol 38: 734-742, incorporated herein by reference) . A lot of people are diagnosed with CRC and many patients die of this disease each year worldwide. Although current strategies, including surgery, radiotherapy, and chemotherapy, have a significant clinical value for CRC, the relapses and metastases of cancers after surgery have hampered the success of those treatment modalities.
Chronic intestinal inflammation occurring in inflammatory bowel disease (IBD) induces persistent damage and enhanced mucosal permeability along the gastrointestinal tract, playing an important role in the development of colorectal cancer (CRC) . Together with the hereditary syndromes of familial adenomatous polyposis and hereditary nonpolyposis, IBD is among the top three high-risk conditions for CRC (Xie J, Itzkowitz SH (2008) Cancer in inflammatory bowel disease. World J Gastroenterol 14: 378-389, incorporated herein by reference) . Among ulcerative colitis (UC) patients, one of the two main manifestations of IBD, the relative risk of developing CRC correlates with the extent and duration of disease (Eaden JA, Abrams KR, Mayberry JF (2001) The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 48： 526-535, incorporated herein by reference) . In patients with IBD, this risk increases by 0.5-1.0％ yearly after 8-10 years (Munkholm P (2003) Review article: the incidence and  prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18 Suppl 2: 1-5, incorporated herein by reference) .
The human gut microflora, which contains about 100 trillion microbial organisms, plays a critical role in maintaining host health, both in the gastrointestinal tract and systemically through the absorption of metabolites (e. g. vitamins and short chain fatty acids) (Moore WE, Holdeman LV (1974) Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol 27: 961-979, incorporated herein by reference) . Recent studies have demonstrated that specific strains of bacteria are implicated in the regulation of the intestinal homeostasis, delivering regulatory signals to the epithelium, the mucosal immune system and to the neuromuscular activity of the gut (Shanahan F (2004) Probiotics in inflammatory bowel disease-therapeutic rationale and role. Adv Drug Deliv Rev 56: 809-818, incorporated herein by reference) . Moreover, some commensal and pathogenic organisms of the human enteric microbiome are essential in the pathogenesis of IBD and CRC. Therefore, manipulating the gut bacterial composition and local metabolite production by using probiotic bacteria has been explored as a promising avenue for therapeutic intervention against CRC. Probiotics are live microbial feed supplements which beneficially impact on host health. They rely on introducing particular exogenous strains into the gut microflora. For the study of CRC, the inventors performed analysis in the metagenomics field, presenting data from deep metagenomic profiling of CRC gut microbiome, .
SUMMARY
Embodiments of the present disclosure seek to solve at least one of the problems existing in the prior art to at least some extent.
The present invention is based on the following findings by the inventors:
Assessment and characterization of gut microbiota has become a major research area in human disease, including colorectal cancer (CRC) , one of the commonest causes of death among all types of cancers. To carry out analysis on gut microbial content in CRC patients, the inventors carried out a protocol for a Metagenome-Wide Association Study (MGWAS) (Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012) , incorporated herein by reference) based on deep shotgun sequencing of the gut microbial DNA from 128 Chinese individuals. The inventors identified 2 probiotic bacteria. Then the  inventors validated the probiotic bacteria in animal experiment related to colitis and CRC respectively. Results from the animal experiment demonstrated the ability of Eubacterium ventriosum and Eubacterium eligens to prevent and treat both colitis and colorectal cancer effectively.
BRIEF DISCRIPTION OF DRAWINGS
These and other aspects and advantages of the present disclosure will become apparent and more readily appreciated from the following descriptions taken in conjunction with the drawings, in which:
Fig. 1 shows distribution of P-value association statistics of all microbial genes in this study. The association analysis of CRC p-value distribution identified a disproportionate over-representation of strongly associated markers at lower P-values, with the majority of genes following the expected P-value distribution under the null hypothesis. This suggests that the significant markers likely represent true rather than spurious associations.
Fig. 2 Protective effects of intragastric administration of Eubacterium ventriosum ATCC 27560， Eubacterium ventriosum L2-12， Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750， Eubacterium eligens STAFF 1020， Eubacterium eligens TSDC10.2-1.1 respectively on DSS-induced colitis in C57Bl/6J considering (A) weight loss, (B) disease activity index and (C) Colon length. Data are represented as mean±standard error. Different asterisks (*) indicate significant differences (*P<0.05, **P<0.01, ***p<0.001) .
Fig. 3 Quantification using ELISA of (A) TNF-αand (B) IL-10 in colons obtained at day 15 after induction of colitis. Data are represented as mean±standard error. Different asterisks (*) indicate significant differences (*P<0.05, **P<0.01, ***p<0.001)
Fig. 4 Effect of Eubacterium ventriosum ATCC 27560， Eubacterium ventriosum L2-12， Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750， Eubacterium eligens STAFF 1020， Eubacterium eligens TSDC10.2-1.1 respectively treatment on (A) _Disease activity indices and (B) colon histopathology. Different asterisks (*) indicate significant differences (*P<0.05, **P<0.01, ***p<0.001)
Fig. 5 Eubacterium ventriosum ATCC 27560， Eubacterium ventriosum L2-12， Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750， Eubacterium eligens STAFF 1020， Eubacterium eligens TSDC10.2-1.1 respectively modulate colonic gene expression  in BABL/C mice (relatived withβ-actin) . Data are represented as meant±standard error. Different asterisks (*) indicate significant differences (*P<0.05, **P<0.01, ***p<0.001) .
DETAILED DESCRIPTION
Terms used herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the present invention. Terms such as “a” ， “an” and “the” are not intedded to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not delimit the invention, except as outlined in the claims.
In one aspect, the present application provides Eubacterium eligens or Eubacterium ventriosum for use in the prevention or treatment of colitis and/or colorectal cancer. In another aspect, the present application provides use of Eubacterium eligens or Eubacterium ventriosum for manufacture of a medicament for prevention or treatment of colitis and/or colorectal cancer. In another aspect, the present application provides a method for the prevention or treatment of colitis and/or colorectal cancer comprising administering an effective amount of Eubacterium eligens or Eubacterium ventriosum to a patient in need thereof. In yet another aspect, the present application provides a kit comprising Eubacterium eligens or Eubacterium ventriosum and instructions for its use as a medicament. The present application further provides a pharmaceutical composition comprising Eubacterium eligens or Eubacterium ventriosum and a pharmaceutically acceptable vehicle.
Preferably, the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC10.2-1.1. Preferably, the Eubacterium ventriosum is a strain selected from the group consisting of Eubacterium ventriosum ATCC27560, Eubacterium ventriosum L2-12, and Eubacterium ventriosum STAFF 1042. In one embodiment, the Eubacterium eligens or Eubacterium ventriosum is administered in the form of living Eubacterium eligens or Eubacterium ventriosum or metabolites thereof.
The present invention is further exemplified in the following non-limiting Examples. Unless otherwise stated, parts and percentages are by weight and degrees are Celsius. As apparent to one of ordinary skill in the art, these Examples, while indicating preferred embodiments of the  invention, are given by way of illustration only, and the agents were all commercially available.
EMBODIMENT
Example 1. Identifying probiotic bacteria from 128 Chinese individuals
1.1 Sample collection and DNA extraction
Stool samples from 128 subjects, including 74 colorectal cancer patients and 54 healthy controls (Table 1) were collected in the Prince of Wales Hospital with informed consent. To be eligible for inclusion in this study, individuals have to fit the following criteria for stool sample collection: 1) no taking of antibiotics or other medications with no particular diets (diabetics, vegetarians, etc) and with normal lifestyle (without extra stress) for a minimum of 3 months； 2) a minimum of 3 months after any medical intervention； 3) no history of colorectal surgery, any kind of cancer, or inflammatory or infectious diseases of the intestine. Subjects were asked to collect stool samples before colonoscopy examination in standardized containers at home and store samples in their home freezer immediately. Frozen samples were then delivered to the Prince of Wales Hospital in insulating polystyrene foam containers and stored at-80℃ immediately until use.
Stool samples were thawed on ice and DNA extraction was performed using the QiagenQIAamp DNA Stool Mini Kit according to manufacturer's instructions. Extracts were treated with DNase-free RNase to eliminate RNA contamination. DNA quantity was determined using NanoDrop spectrophotometer, Qubit Fluorometer (with the Quant-iTTMdsDNA BR Assay Kit) and gel electrophoresis.
Table 1 | Baseline characteristics of colorectal cancer cases and controls in the cohort I. BMI: body mass index； eGFR: epidermal growth factor receptor； DM: diabetes mellitus type 2.
Parameter Controls (n＝54)  Cases (n＝74) 
Age 61.76 66.04
Sex (M: F)  33: 21 48: 26
BMI 23.47 23.9
eGFR 72.24 74.15
DM (％)  16 (29.6％)  29 (39.2％) 
Enterotype (1: 2: 3)  26: 22: 6 37: 31: 6
Stage of disease (1: 2: 3: 4)  n. a. 16: 21: 30: 7
Location (proximal: distal)  n. a. 13: 61
1.2 DNA library construction and sequencing
DNA library construction was performed following the manufacturer's instruction (IIlumina  HiSeq 2000 platform). The inventors used the same workflow as described previously to perform cluster generation, template hybridization, isothermal amplification, linearization, blocking and denaturation, and hybridization of the sequencing primers (Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012), incorporated herein by reference) .
The inventors constructed one paired-end (PE) library with insert size of 350bp for each sample, followed by a high-throughput sequencing to obtain around 30 million PE reads of length 2x100bp. High quality reads were extracted by filtering low quality reads with ‘N’ base， adapter contamination and human DNA contamination from the raw data, and by trimming low quality terminal bases of reads at the same time. 751 million metagenomic reads (high quality reads) were generated (5.86 million reads per individual on average, Table 2) .
1.3 Reads mapping
The inventors mapped the high quality reads to the gene catalogue (Table 2) to a published reference gut gene catalogue established from European and Chinese adults (Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012), incorporated herein by reference) (identity >＝90％) , based on which the inventors derived the gene profiles using the same method of the published T2D paper in Qin et al. 2012, supra. From the reference gene catalogue as Qin et al. 2012, supra, the inventors derived a subset of 2,110,489 (2.1M) genes that appeared in at least 6 samples in all 128 Hong Kong samples.
Table 2. Summary of metagenomic data and mapping to reference gene catalogue. Fourth column reports results from Wilcoxon rank-sum tests.
Parameter Controls Cases P-value
Average raw reads 60162577 60496561 0.8082
After removing low quality reads 59423292 (98.77％)  59715967 (98.71％)  0.831
After removing human reads 59380535±7378751 58112890±10324458 0.419
Mapping rate 66.82％ 66.27％ 0.252
1.4 Analysis of factors influencing gut microbiota gene profiles
To ensure robust comparison of the gene content of 128 metagenomes, the inventors created a set of 2,110,489 (2.1M) genes that were present in at least 6 subjects, and generated 128 gene abundance profiles using these 2.1 million genes. The inventors used the permutational  multivariate analysis of variance (PERMANOVA) test to assess the effect of different characteristics, including age, BMI, eGFR, TCHO, LDL, HDL, TG, gender, DM, CRC status, smoking status and location, on gene profiles of 2.1M genes. The inventors performed the analysis using the method implemented in package “vegan” in R, and the permuted p-value was obtained by 10,000 times permutations. The inventors also corrected formultiple testing using “p. adjust” in R with Benjamini-Hochberg method to get the q-value for each gene.
When the inventors performed permutational multivariate analysis of variance (PERMANOVA) on 13 different covariates, only CRC status was significantly associated with these gene profiles (q＝0.0028, Table 3) , showing a stronger association than the second best determinant body mass index (q＝0.15) . Thus the data suggest an altered gene composition in CRC patient microbiomes.
Table 3. PERMANOVA analysis using microbial gene profile. The analysis was conducted to test whether clinical parameters and colorectal cancer (CRC) status have significant impact on the gut microbiota with q<0.05. BMI: body mass index； DM: diabetes mellitus type 2； HDL: high density lipoprotein； TG: triglyceride； eGFR: epidermal growth factor receptor； TCHO: total cholesterol； LDL； low density lipoprotein.
Phenotype Df SumsOfSqs MeanSqs F. Model R2 Pr (>F)  q-value
CRC Status
1 0.679293 0.679293 1.95963 0.015314 0.0004 0.0028
BMI 1 0.484289 0.484289 1.39269 0.011019 0.033 0.154
DM Status 1 0.438359 0.438359 1.257642 0.009883 0.084 0.27272
Location 1 0.436417 0.436417 1.228172 0.016772 0.0974 0.27272
Age 1 0.397282 0.397282 1.138728 0.008957 0.1923 0.4487
HDL 1 0.38049 0.38049 1.083265 0.010509 0.271 0.542
TG 1 0.365191 0.365191 1.039593 0.010089 0.3517 0.564964
eGFR 1 0.358527 0.358527 1.023138 0.009471 0.38 0.564964
CRC Stage 1 0.357298 0.357298 1.002413 0.013731 0.441 0.564964
Smoker 1 0.347969 0.347969 0.999825 0.013511 0.4439 0.564964
TCHO 1 0.321989 0.321989 0.915216 0.008893 0.6539 0.762883
LDL 1 0.306483 0.306483 0.871306 0.00847 0.7564 0.814585
Gender 1 0.267738 0.267738 0.765162 0.006036 0.9528 0.9528
1.5 CRC-associated genes identified by MGWAS
1.5.1 Identification of colorectal cancer associated genes. The inventors performed a metagenome wide association study (MGWAS) to identify the genes contributing to the altered gene composition in CRC. To identify the association between the metagenomic profile and  colorectal cancer, a two-tailed Wilcoxon rank-sum test was used in the 2.1M (2,110,489) gene profiles. The inventors got 140, 455 gene markers, _which were enriched in either case or control with P<0.01 (Fig. 1) .
1.5.2 Estimating the false discovery rate (FDR) . Instead of a sequential P-value rejection method, the inventors applied the “qvalue” method proposed in a previous study (J. D. Storey, R. Tibshirani, Statistical significance for genomewide studies. Proceedings of the National Academy of Sciences of the United States of America 100, 9440 (Aug 5, 2003) , incorporated herein by reference) to estimate the FDR. In the MGWAS, the statistical hypothesis tests were performed on a large number of features of the 140, 455 genes. The false discovery rate (FDR) was 11.03％.
1.6 Data profile construction
Basing on the sequencing reads of the 128 microbiomes abtained above, the inventors examined the taxonomic differences between control and CRC-associated microbiomes to identify microbial taxa contributing to the dysbiosis. For this, the inventors used taxonomic profiles derived from three different methods, as supporting evidence from multiple methods would strengthen an association. First, the inventors mapped metagenomic reads to 4650 microbial genomes in the IMG database (version 400) and estimated the abundance of microbial species included in that database (denoted IMG species) . Second, the inventors estimated the abundance of species-level molecular operational taxonomic units (mOTUs) using universal phylogenetic marker genes. Third, the inventors organized the 140, 455 genes identified by MGWAS into metagenomic linkage groups (MLGs) that represent clusters of genes originating from the same genome, annotated the MLGs at species level using IMG database whenever possible, grouped MLGs based on these species annotations, and then estimated the abundance of these species (denoted MLG species) .
1.6.1 Species annotation of IMG genomes
For each IMG genome, using the NCBI taxonomy identifier provided by IMG, the inventors identified the corresponding NCBI taxonomic classification at species and genus levels using NCBI taxonomy dump files. The genomes without corresponding NCBI species names were left with its original IMG names, most of which were unclassified.
1.6.2 Gene profiles
The inventors mapped our high-quality reads to the gene catalogue to a published reference  gut gene catalogue established from European and Chinese adults (Qin, J. et al. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature 490, 55-60 (2012) , incorporated herein by reference) (identity >＝90％) , based on which the inventors derived the gene profiles using the same method of the published T2D paper as Qin et al. 2012, supra.
1.6.3 mOTU profile
Clean reads (high quality reads in Example 1) were aligned to mOTU reference (total 79268 sequences) with default parameters (S. Sunagawa et al. , Metagenomic species profiling using universal phylogenetic marker genes. Nature methods 10, 1196 (Dec, 2013) , incorporated herein by reference) . 549 species level mOTUs were identified, including 307 annotated species and 242 mOTU linkage groups without representative genomes, which were putatively Firmicutes or Bacteroidetes.
1.6.4 IMG-species and IMG-genus profiles
Bacterial, archaeal and fungal sequences were extracted from IMG v400 reference database (V. M. Markowitz et al. , IMG: the Integrated Microbial Genomes database and comparative analysis system. Nucleic acids research 40, D115 (Jan, 2012) , incorporated herein by reference) downloaded from http: //ftp. jgi-psf. org. 522, 093 sequences were obtained in total, and SOAP reference index was constructed based on 7 equal size chunks of the original file. Clean reads were aligned to reference using SOAP aligner (R. Li et al. , SOAP2: an improved ultrafast tool for short read alignment. Bioinformatics 25, 1966 (Aug 1, 2009) , incorporated herein by reference) version 2.22, with parameters “-m 4-s 32-r 2-n 100-x 600-v 8-c 0.9-p 3” . Then， SOAP coverage software was used to calculate read coverage of each genome, normalized with genome length, and further normalized to relative abundance for each individual sample. The profile was generated based on uniquely mapped reads only.
1.7 Identification of colorectal cancer associated species
Based on the identified 140, 455 colorectal cancer associated maker genes profile, the inventors constructed the colorectal cancer associated MLGs using the method described in the previous type 2 diabetes study as Qin et al. 2012, supra. All genes were aligned to the reference genomes of IMG database v400 to get genome level annotation. An MLG was assigned to a genome if > 50％ constitutive genes were annotated to that genome, otherwise it was termed as unclassified. Total 87 MLGs with gene number over than 100 were selected as colorectal cancer associated MLGs. These MLGs were grouped based on the species annotation of these genomes to  construct MLG species.
To estimate the relative abundance of an MLG species, the inventors estimated the average abundance of the genes of the MLG species, after removing the 5％ lowest and 5％ highest abundant genes. Relative abundance of IMG species was estimated by summing the abundance of IMG genomes belonging to that species.
These analysis identified 30 IMG species, 21 mOTUs and 86 MLG species that were significantly associated with CRC status (Wilcoxon rank-sum test, q<0.05； see Tables 4, 5) . Eubacterium ventriosum was consistently enriched in the control microbiomes across all three methods (Wilcoxon rank-sum testu-IMG: q＝0.0414； mOTU: q＝0.012757； MLG: q＝5.446x10-4) , and Eubacterium eligens was enriched according to two methods (Wilcoxon rank-sum tests-IMG: q＝0.069； MLG: q＝0.00031) . These results indicated that both of these two species may have great ability as probiotic bacteria in preventing and treating CRC related diseases.
On the other hand, Parvimonas micra (q<1.80x10-5) , Peptostreptococcus stomatis (q<1.80x10-5) , Solobacterium moorei (q<0.004331) and Fusobacterium nucleatum (q<0.004565) were consistently enriched in CRC patient microbiomes across all three methods. P. stomatis has been associated with oral cancer (S. Pushalkar et al. , Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC microbiology 12, 144 (2012) , incorporated herein by reference) , and S. moorei has been associated with bacteremia (R. M. Pedersen, H. M. Holt, U. S. Justesen, Solobacterium moorei bacteremia: identification, antimicrobial susceptibility, and clinical characteristics. Journal of clinical microbiology 49, 2766 (Jul, 2011) , incorporated herein by reference) . Recent work with 16S rRNA sequencing has observed significant enrichment of F. nucleatum in CRC tumor samples (M. Castellarin et al. , Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome research 22, 299 (Feb, 2012) , incorporated herein by reference) , and this bacteria has been shown to possess adhesive (G. Bachrach, C. Ianculovici, R. Naor, E. I. Weiss, Fluorescence based measurements of Fusobacterium nucleatum coaggregation and of fusobacterial attachment to mammalian cells. FEMS microbiology letters 248, 235 (Jul 15, 2005) , incorporated herein by reference) , invasive (Y. W. Han et al. , Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. Infection and immunity 68, 3140 (Jun, 2000) , incorporated herein by reference) and pro-inflammatory (A. D. Kostic et al. ,  Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment. Cell Host Microbe 14, 207 (2013) , incorporated herein by reference) properties. These results confirmed this association in a new cohort with different genetic and cultural origins. However, a highly significant enrichment of P. micra-an obligate anaerobic bacterium that can cause oral infections like F. nucleatum (G. Sundqvist, Taxonomy, ecology, and pathogenicity of the root canal flora. Oral surgery, oral medicine, and oral pathology 78, 522 (Oct, 1994) , incorporated herein by reference) -in CRC-associated microbiomes is a novel finding. P. micra is involved in the etiology of periodontis (B. H. Kremer et al. , Peptostreptococcus micros smooth and rough genotypes in periodontitis and gingivitis. Journal of periodontology 71, 209 (Feb, 2000) , incorporated herein by reference) , and it produces a wide range of proteolytic enzymes and uses peptones and amino acids as energy source (D. A. Murdoch, H. N. Shah, Reclassification of Peptostreptococcus magnus (Prevot 1933) Holdeman and Moore 1972 as Finegoldia magna comb. nov. and Peptostreptococcus micros (Prevot 1933) Smith 1957 as Micromonas micros comb. nov. Anaerobe 5, 555 (10//, 1999) , incorporated herein by reference) . It is known to produce hydrogen sulphide (J. Carlsson, J. T. Larsen, M. B. Edlund, Peptostreptococcus micros has a uniquely high capacity to form hydrogen sulfide from glutathione. Oral microbiology and immunology 8, 42 (Feb, 1993) , incorporated herein by reference) , which promotes tumor growth and proliferation of colon cancer cells (C. Szabo et al. , Tumor-derived hydrogen sulfide, produced by cystathionine-beta-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer. Proceedings of the National Academy of Sciences of the United States of America 110, 12474 (Jul 23, 2013) , incorporated herein by reference) . Further research is required to verify whether P. micra is involved in the pathogenesis of CRC, or its enrichment is a result of CRC associated changes in the colon and/or rectum. Nevertheless, it may represent opportunities for non-invasive diagnostic biomarkers for CRC.
Example 2. Validation in animal experiment
In order to validate the ability of the probiotic bacteria, Eubacterium ventriosum and Eubacterium eligens, in preventing and treating CRC related diseases, the inventors performed animal experiments.
2.1 Validation in animal experiment related to colitis
2.1.1 Method 
Ten to twelve weeks old C57BL/6J mice used for DSS-induced colitis study were prepared in SPF condition. After acclimatization, part of mice have ad libitum access to drinking water containing 3.5-5％ DSS (dextran sodium sulfate) for five days for colitis induction. Bacterial suspensions of Eubacterium ventriosum ATCC 27560， Eubacterium ventriosum L2-12， Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750， Eubacterium eligens STAFF 1020， Eubacterium eligens TSDC10.2-1.1 (109-1010 cfu/ml, freshly prepared daily) , or medium was administered respectively to mice daily by intragastric gavage from day 1 to day 14 after induction of colitis. No colitis and colitis control groups received medium intragastrically (500μl/50g. BW every day， n＝10 in each group) .
C57BL/6J mice were purchased from Laboratory Animal Center of Southern Medical University, China. Eubacterium ventriosum ATCC 27560 and Eubacterium eligens ATCC 27750 were purchased from American Type Culture Collection (ATCC) .
Eubacterium ventriosum L2-12: Estelle Devillard, Freda M. McIntosh, Sylvia H. Duncan, and R. John Wallace (March 2007) . Metabolism of Linoleic Acid by Human Gut Bacteria: Different Routes for Biosynthesis of Conjugated Linoleic Acid. Journal of Bacteriology 189 (6) : 2566-2570.
Eubacterium ventriosum STAFF 1042, Eubacterium eligens STAFF 1020: Kageyama, A. et al. Rapid detection of human fecal Eubacterium species and related genera by nested PCR method, Microbiology and Immunology (2001) 45 (4) : 315-318.
Eubacterium eligens TSDC10.2-1.1 was purchased from Washington University in St. Louis (USA) http: //www. genomesonline. org/projects？ id＝47012.
Mice were observed daily and recorded clinical measurements. Body weights and the disease activity index (Table 6) (Alex P, Zachos NC, Nguyen T, Gonzales L, Chen TE, Conklin , LS, et al. 2009 Distinct cytokine patterns identified from multiplexprofiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis； 15 (3) : 341-52. incorporated herein by reference. ) , a composite score reflecting clinical signs of the disease (i. e. perianal soiling, rectal bleeding and diarrhea) ， were assessed for mice undergoing the DSS challenge， before DSS administration and weekly after intragastric gavage Inflammation was monitored at day 15 after induction of colitis when the mice were sacrificed by cervical dislocation.
Table 6 Clinical scoring standard
Figure PCTCN2014083688-appb-000001
Figure PCTCN2014083688-appb-000002
The colon was removed, dissected free of fat and mesentery, carefully opened, and cleaned with PBS (phosphate buffered saline) . Colon length was measured. Colonic damage and inflammation were assessed blindly according to the Wallace criteria. Colon was also collected into liquid nitrogen and stored at-80℃ for ELISA (Enzyme Linked Immunosorbent Assay) examinations.
2.1.2 Results
2.1.2.1 Severity of DSS-Induced Colitis in Mice Was Reduced by Eubacterium ventriosum ATCC 27560， Eubacterium ventriosum L2-12， Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750， Eubacterium eligens STAFF 1020， Eubacterium eligens TSDC10.2-1.1 respectively.
The inventors explored the anti-inflammatory effects in vivo by testing the ability of E. eligens ATCC 27750, STAFF 1020, TSDC10.2-1.1 and E. ventriosum L2-12, STAFF 1042, ATCC 27560 respectively to recover acute colitis induced by DSS. A severe acute inflammatory was observed in the colitis control group after DSS treated, and no significant protective effect was observed in mice receiving sterile culture medium. In contrast, daily intragastric administration of 6 living Eubacterium strains respectively all resulted in a marked attenuation of colitis with reduced weight loss (Table 7, Fig. 2A) , and decreasing disease activity index associated with colitis at the 7th and 14th day after intragastric gavage (the profiles of the data at 7th day were similar with those at the 14th day which was not shown here. ) . And partial colon length were normalized in comparison to the medium treated group (Table 8, Fig. 2B、2C) . There was no difference in body weight and disease activity index at the beginning of intragastric gavage. Data were represented as mean±standard error
Table 7 Data of Body weight (W0: body weight before DSS-treated； W1: body weight at the 7th day after intragastric gavage )
Figure PCTCN2014083688-appb-000003
Figure PCTCN2014083688-appb-000004
*ATCC 27560 represents Eubacterium ventriosum ATCC 27560； L2-12 represents Eubacterium ventriosum L2-12， STAFF 1042 represents Eubacterium ventriosum STAFF 1042, ATCC 27750 represents Eubacterium eligens ATCC 27750， STAFF 1020 represents Eubacterium eligens STAFF 1020, TSDC10.2-1.1 represents Eubacterium eligens TSDC10.2-1.1.
Table 8 Data of clinical measurements related to colitis
Figure PCTCN2014083688-appb-000005
2.1.2.2 Eubacterium ventriosum ATCC 27560, Eubacterium ventriosum L2-12, Eubacterium ventriosum STAFF 1042, Eubacterium eligens ATCC 27750， Eubacterium eligens STAFF 1020, Eubacterium eligens TSDC10.2-1.1 modulate expression of colonic inflammatory respectively
Colonic proinflammatory TNF-α (tumor necrosis factor alpha) cytokines and anti-inflammatory IL-10 (interleukin-10) were quantified by ELISA. Compared with the no-colitis control group, TNF-α levels was increased, whereas IL-10 levels were barely modified in the colitis mice. After treated with suspensions of E. eligens ATCC 27750, the secrition of TNF-α (Fig. 3A, Table 8) was significantly lower than in the colitis control and medium groups. Meanwhile, IL-10 secretion was induced in the colon of mice treated with ATCC 27750 (Fig. 3B, Table 8) . Similar phenomenon ？ were observed in C57Bl/6J mice administration with E.  ventriosum ATCC 27560, E. ventriosum L2-12, E. ventriosum STAFF 1042, E. eligens STAFF 1020 and E. eligens TSDC10.2-1.1 (Fig. 3, Table 8 ) .
2.2 Validation in animal experiment related to colorectal cancer
2.2.1 Method
The BABL/c mice were challenged with azoxymethane (AOM, 10 mg/kg) at the age of 10 weeks followed by a 2.0％ dextran sodium sulfate (DSS) treatment in the drinking water for 7 days beginning on week 2, week 5 and week 8 to induce colitis-associated colorectal cancer (CRC) . Then mice were treated with Eubacterium ventriosum ATCC 27560， L2-12， STAFF 1042, and Eubacterium eligens ATCC 27750， STAFF 1020, TSDC10.2-1.1 (109-1010 cfu/ml , freshly prepared daily) , or control medium respectively from week 9 of the study until killing by cervical dislocation on week 11 (0.1ml /50 g. BW every day, n＝15 in each group) . BABL/c mice were purchased from Laboratory Animal Center of Southern Medical University, China.
Disease activity index was calculated as previous described, which was assessed for mice undergoing the AOM+DSS challenge, before and weekly after intragastric gavage.
For histopathology examination, after the necropsy, colonic sections were fixed in 10％ buffered neutral formalin， later embedded in paraffin， and then sectioned (6μm) and stained with H&E (Hematoxylin and eosin) . Tissue slides were examined in an Olympus microscope (lympus America Inc. , Dulles, VA) . Specimens underwent blinded histological examination and were scored 1-4 on adenomas and adenocarcioomas.
For RNA isolation and real-time polymerase chain reaction of cytokines, tTotal RNA from colon was isolated using the Qiagen RNA isolation kit (Qiagen) according to the manufacturer’s instructions, and then was used to generate the cDNA template using the iScript cDNA synthesis kit (Bio-Rad, Hercules, CA) and real-time RT-PCR was performed as previously described (Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, et al. (2004) Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroen-terology 127: 777-791， incorporated herein by reference) . mRNA expression of CD36， and PPARγ (peroxisome proliferator-activated receptor γ) wereassessed by real-time quantitative PCR.
2.2.2 Results
2.2.2.1 After daily administrated with E. ventriosum L2-12 or E. ventriosum STAFF 1042 or  E. ventriosum ATCC 27560 or E. eligens STAFF 1020 or E. eligens TSDC10.2-1.1 or E. eligens ATCC 27750 for 2 weeks, the disease activity index were significantly lower than CRC control group (Table 9) , while no difference was shown in the models of inflammation-driven colorectal cancer before intragastric gavage (data was not shown here) . And the effect of six Eubacterium strains treatments respectively on colon histopathology of experimental azoxymethane-induced colorectal cancer were detected, and all these treatments diminished adenoma and adenocarcinoma formation when compared to the control (Fig. 4， Table 9 ) .
2.2.2.2 E. ventriosum L2-12 or E. ventriosum STAFF 1042 or E. ventriosum ATCC 27560 or E. eligens STAFF 1020 or E. eligens TSDC10.2-1.1 or E. eligens ATCC 27750 modulate expression of colonic inflammatory and carcinogenesis markers respectively.
Mice challenged with azoxymethane and DSS were euthanized in the tumor-bearing phase of the disease. Those mice treated with E. eligens ATCC 27750 or E. eligens STAFF 1020 or E. eligens TSDC10.2-1.1 or E. ventriosum L2-12 or E. ventriosum STAFF 1042 or E. ventriosum ATCC 27560 shoeed increased mRNA expression of CD36 and PPARγ in the colon compared with medium-treated control group (Fig. 5, Table 9) .
Table 9 Data of clinical measurements related to CRC
Figure PCTCN2014083688-appb-000006
Above all, results from this study demonstrate the ability of E. ventriosum L2-12 or E. ventriosum STAFF 1042 or E. ventriosum ATCC 27560 or E. eligens STAFF 1020 or E. eligens TSDC10.2-1.1 or E. eligens ATCC 27750 to ameliorate both colitis and colorectal cancer.
Figure PCTCN2014083688-appb-000007
Figure PCTCN2014083688-appb-000008
Figure PCTCN2014083688-appb-000009
Figure PCTCN2014083688-appb-000010
Figure PCTCN2014083688-appb-000011
[Corrected under Rule 26, 16.09.2014]
Although explanatory embodiments have been shown and described, it would be appreciated by those skilled in the art that the above embodiments can not be construed to limit the present disclosure, and changes, alternatives, and modifications can be made in the embodiments without departing from spirit, principles and scope of the present disclosure.

Claims (13)

  1. Eubacterium eligens for use in the prevention or treatment of colitis and/or colorectal cancer.
  2. The Eubacterium eligens for use according to claim 1, wherein the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC10.2-1.1.
  3. The Eubacterium eligens for use according to claim 1 or claim 2, wherein the Eubacterium eligens is administered in the form of living Eubacterium eligens or metabolites thereof.
  4. Use of Eubacterium eligens for manufacture of a medicament for prevention or treatment of colitis and/or colorectal cancer.
  5. The use according to claim 4, wherein the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC10.2-1.1.
  6. The use according to claim 4 or claim 5, wherein the Eubacterium eligens is administered in the form of living Eubacterium eligens or metabolites thereof.
  7. A method for the prevention or treatment of colitis and/or colorectal cancer comprising administering an effective amount of Eubacterium eligens to a patient in need thereof.
  8. The method of claim 7, wherein the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC10.2-1.1.
  9. The method of claim 7 or claim 8, wherein the Eubacterium eligens is administered in the form of living Eubacterium eligens or metabolites thereof.
  10. A kit comprising Eubacterium eligens and instructions for its use as a medicament.
  11. The kit of claim 10, wherein the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens STAFF 1020 and Eubacterium eligens TSDC10.2-1.1.
  12. A pharmaceutical composition comprising Eubacterium eligens and a pharmaceutically acceptable vehicle.
  13. The pharmaceutical composition of claim 12, wherein the Eubacterium eligens is a strain selected from the group consisting of Eubacterium eligens ATCC 27750, Eubacterium eligens  STAFF 1020 and Eubacterium eligens TSDC10.2-1.1.
PCT/CN2014/083688 2014-08-05 2014-08-05 Use of eubacterium in the prevention and treatment for colorectal cancer related diseases WO2016019505A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201480080819.1A CN106573044B (en) 2014-08-05 2014-08-05 Use of eubacterium for preventing and treating colorectal cancer-related diseases
PCT/CN2014/083688 WO2016019505A1 (en) 2014-08-05 2014-08-05 Use of eubacterium in the prevention and treatment for colorectal cancer related diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2014/083688 WO2016019505A1 (en) 2014-08-05 2014-08-05 Use of eubacterium in the prevention and treatment for colorectal cancer related diseases

Publications (1)

Publication Number Publication Date
WO2016019505A1 true WO2016019505A1 (en) 2016-02-11

Family

ID=55262988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2014/083688 WO2016019505A1 (en) 2014-08-05 2014-08-05 Use of eubacterium in the prevention and treatment for colorectal cancer related diseases

Country Status (2)

Country Link
CN (1) CN106573044B (en)
WO (1) WO2016019505A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018036503A1 (en) * 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
WO2019028402A1 (en) 2017-08-04 2019-02-07 Second Genome, Inc. Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114438214B (en) * 2018-06-27 2023-12-22 深圳华大生命科学研究院 Colorectal cancer tumor marker and detection method and device thereof
CN110150228A (en) * 2019-06-04 2019-08-23 于涛 A kind of construction method of diabetic mice colorectal carcinoma model
CN111205994B (en) * 2019-10-23 2021-09-21 上海市第十人民医院 Fusobacterium nucleatum subspecies animal strain and application thereof
CN110903998B (en) * 2019-10-23 2021-09-21 上海市第十人民医院 Intestinal tract separated fusobacterium nucleatum Wenzeri strain and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
CN101590081A (en) * 2008-05-28 2009-12-02 青岛东海药业有限公司 Eubacterium ventriosum and Eubacterium biforme preparation and application thereof
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
WO2013037068A1 (en) * 2011-09-14 2013-03-21 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990001335A1 (en) * 1988-08-02 1990-02-22 Borody Thomas J Treatment of gastro-intestinal disorders
CN101590081A (en) * 2008-05-28 2009-12-02 青岛东海药业有限公司 Eubacterium ventriosum and Eubacterium biforme preparation and application thereof
WO2012142605A1 (en) * 2011-04-15 2012-10-18 Samaritan Health Services Rapid recolonization deployment agent
WO2013037068A1 (en) * 2011-09-14 2013-03-21 Queen's University At Kingston Method for treatment of disorders of the gastrointestinal system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PETROF E.O. ET AL.: "Stool substitute transplant therapy for the eradication of Clostridium difficile infection:'RePOOPulating' the gut.", MICROBIOME, vol. 1, no. 3, 31 December 2013 (2013-12-31) *
YANG L.Y. ET AL.: "Bacteria, inflammation, and colon cancer.", WORLD JOURNAL OF GASTROENTEROLOGY, vol. 12, no. 42, 14 November 2006 (2006-11-14) *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11266698B2 (en) 2011-10-07 2022-03-08 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
US11224620B2 (en) 2016-07-13 2022-01-18 4D Pharma Plc Compositions comprising bacterial strains
WO2018036503A1 (en) * 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
US11007233B2 (en) 2017-06-14 2021-05-18 4D Pharma Research Limited Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
US11123379B2 (en) 2017-06-14 2021-09-21 4D Pharma Research Limited Compositions comprising bacterial strains
US11660319B2 (en) 2017-06-14 2023-05-30 4D Pharma Research Limited Compositions comprising bacterial strains
US11779613B2 (en) 2017-06-14 2023-10-10 Cj Bioscience, Inc. Compositions comprising a bacterial strain of the genus Megasphera and uses thereof
WO2019028402A1 (en) 2017-08-04 2019-02-07 Second Genome, Inc. Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics
CN111163785A (en) * 2017-08-04 2020-05-15 第二基因组股份有限公司 Human Roseburia, Pectiganella and combinations thereof as biotherapeutics
EP3661525A4 (en) * 2017-08-04 2020-07-22 Second Genome, Inc. Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics

Also Published As

Publication number Publication date
CN106573044B (en) 2020-01-21
CN106573044A (en) 2017-04-19

Similar Documents

Publication Publication Date Title
WO2016019506A1 (en) Use of eubacterium in the prevention and treatment for colorectal cancer related diseases
WO2016019505A1 (en) Use of eubacterium in the prevention and treatment for colorectal cancer related diseases
Sun et al. The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management
Urbaniak et al. The microbiota of breast tissue and its association with breast cancer
Stringer et al. Irinotecan‐induced mucositis manifesting as diarrhoea corresponds with an amended intestinal flora and mucin profile
Sun et al. Evolutionary biologic changes of gut microbiota in an ‘adenoma-carcinoma sequence’mouse colorectal cancer model induced by 1, 2-Dimethylhydrazine
Delchier et al. Efficacy of a tailored PCR-guided triple therapy in the treatment of Helicobacter pylori infection
Taverniti et al. Probiotics modulate mouse gut microbiota and influence intestinal immune and serotonergic gene expression in a site-specific fashion
Xiao et al. Oral microbiota transplantation fights against head and neck radiotherapy-induced oral mucositis in mice
He et al. Probiotics mitigate Helicobacter pylori‐induced gastric inflammation and premalignant lesions in INS‐GAS mice with the modulation of gastrointestinal microbiota
Zhang et al. Development of an XBP1 agonist, HLJ2, as a potential therapeutic agent for ulcerative colitis
Wang et al. Synonymous point mutation of gtfB gene caused by therapeutic X-rays exposure reduced the biofilm formation and cariogenic abilities of Streptococcus mutans
Zeber-Lubecka et al. Increased diversity of a cervical microbiome associates with cervical cancer
Liu et al. Shifts and importance of viable bacteria in treatment of DSS-induced ulcerative colitis mice with FMT
WO2016049827A1 (en) Use of bacteroides in prevention and treatment for coronary artery disease
Gong et al. Mesenteric adipose tissue‐derived Klebsiella variicola disrupts intestinal barrier and promotes colitis by type VI secretion system
Al-Ouqaili et al. Study of vacuolating cytotoxin A (vacA) genotypes of ulcerogenic and non-ulcerogenic strains of Helicobacter pylori and its association with gastric disease
Hinshaw et al. Hedgehog blockade remodels the gut microbiota and the intestinal effector CD8+ T cells in a mouse model of mammary carcinoma
Zhang et al. Qi-Long-Tian capsule alleviates pulmonary fibrosis development by modulating inflammatory response and gut microbiota
Tiwari et al. Polymerase chain reaction based analysis of the cytotoxin associated gene pathogenicity island of Helicobacter pylori from saliva: an approach for rapid molecular genotyping in relation to disease status
Zhang et al. Probiotics treatment ameliorated mycophenolic acid-induced colitis by enhancing intestinal barrier function and improving intestinal microbiota dysbiosis in mice
WO2021004373A1 (en) Use of mate1 gene in treatment of colorectal cancer
Zhang et al. Oral Metformin Inhibits Choroidal Neovascularization by Modulating the Gut-Retina Axis
Wu et al. Therapeutic targeting of vimentin by ALD-R491 impacts multiple pathogenic processes to attenuate acute and chronic colitis in mice
Bakadia et al. Microbiome as cancer biomarkers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14899428

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14899428

Country of ref document: EP

Kind code of ref document: A1